{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:49Z","timestamp":1792872829353,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860298"],"award-info":[{"award-number":["81860298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.biopha.2021.111289","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T21:39:51Z","timestamp":1613079591000},"page":"111289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function"],"prefix":"10.1016","volume":"137","author":[{"given":"Xinghui","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huicong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-5293","authenticated-orcid":false,"given":"Kaijiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111289_bib0005","first-page":"715","article-title":"One year in review 2019: systemic lupus erythematosus","volume":"37","author":"Zucchi","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.biopha.2021.111289_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19874309","article-title":"Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus","volume":"11","author":"Magro","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.biopha.2021.111289_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.berh.2017.10.002","article-title":"Diagnostic and prognostic tests in systemic lupus erythematosus","volume":"31","author":"Vasquez-Canizares","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2021.111289_bib0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/imt-2019-0002","article-title":"Immunometabolism: an overview and therapeutic prospects in autoimmune diseases","volume":"11","author":"Stathopoulou","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2021.111289_bib0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2017.43","article-title":"Immunometabolism in systemic lupus erythematosus","volume":"13","author":"Morel","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2021.111289_bib0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/BOR.0000000000000474","article-title":"Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy","volume":"30","author":"Lo","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.biopha.2021.111289_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/nan.12463","article-title":"Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy","volume":"44","author":"Marsan","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biopha.2021.111289_bib0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000484629","article-title":"mTOR as regulator of lifespan, aging, and cellular senescence: a mini-review","volume":"64","author":"Weichhart","year":"2018","journal-title":"Gerontology"},{"key":"10.1016\/j.biopha.2021.111289_bib0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10295-016-1834-7","article-title":"An overview of rapamycin: from discovery to future perspectives","volume":"44","author":"Yoo","year":"2017","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.biopha.2021.111289_bib0050","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/TP.0000000000002769","article-title":"Mammalian target of rapamycin inhibitors combined with calcineurin inhibitors as initial immunosuppression in renal transplantation: a meta-analysis","volume":"103","author":"Montero","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.biopha.2021.111289_bib0055","first-page":"D4290","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"12","author":"Hahn","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2021.111289_bib0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.09.022","article-title":"Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway","volume":"50","author":"He","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.biopha.2021.111289_bib0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12756","article-title":"mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging","volume":"1346","author":"Perl","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2021.111289_bib0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.111289_bib0075","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.4049\/jimmunol.1301859","article-title":"Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus","volume":"192","author":"Kato","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0080","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s10067-017-3811-6","article-title":"Pristane-induced lupus: considerations on this experimental model","volume":"36","author":"Freitas","year":"2017","journal-title":"Clin. Rheunatol."},{"key":"10.1016\/j.biopha.2021.111289_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.11.006","article-title":"Oxidative stress and immune complexes: pathogenic mechanisms in pristane induced murine model of lupus","volume":"225","author":"Pannu","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2021.111289_bib0090","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1038\/s41598-017-16999-7","article-title":"A novel human systemic lupus erythematosus model in humanised mice","volume":"7","author":"Gunawan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.111289_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4110\/in.2016.16.1.1","article-title":"Regulation of Th2 cell immunity by dendritic cells","volume":"16","author":"Na","year":"2016","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2021.111289_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139845","article-title":"Modulation of dendritic cell activation and subsequent Th1 cell polarization by lidocaine","volume":"10","author":"Jeon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.111289_bib0105","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1002\/eji.201445390","article-title":"NK cells modulate the lung dendritic cell-mediated Th1\/Th17 immunity during intracellular bacterial infection","volume":"45","author":"Shekhar","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nri3771","article-title":"Dendritic cell metabolism","volume":"15","author":"Pearce","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.111289_bib0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11306-015-0772-0","article-title":"Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin","volume":"11","author":"Perl","year":"2015","journal-title":"Metabolomics"},{"key":"10.1016\/j.biopha.2021.111289_bib0125","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.18632\/aging.100925","article-title":"Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL\/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway","volume":"8","author":"Gu","year":"2016","journal-title":"Aging"},{"key":"10.1016\/j.biopha.2021.111289_bib0130","first-page":"79","article-title":"Regulatory T cells and TH1\/TH2 cytokines as immunodiagnosis keys in systemic autoimmune diseases","volume":"69","author":"Ursaciuc","year":"2010","journal-title":"Roum. Arch. Microbiol. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coi.2014.01.006","article-title":"Metabolism of activated T lymphocytes","volume":"27","author":"Maciolek","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/08916934.2019.1693545","article-title":"Th1, Th2, and Th17 cytokines in systemic lupus erythematosus","volume":"53","author":"Muhammad","year":"2020","journal-title":"Autoimmunity"},{"key":"10.1016\/j.biopha.2021.111289_bib0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-94-017-9487-9_3","article-title":"Th1\/Th2 cell\u2019s function in immune system","volume":"841","author":"Zhang","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2021.111289_bib0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phymed.2018.03.057","article-title":"Flavonoids as Th1\/Th2 cytokines immunomodulators: a systematic review of studies on animal models","volume":"44","author":"Gandhi","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2021.111289_bib0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","article-title":"Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity","volume":"72","author":"Talaat","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2021.111289_bib0160","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4927530","article-title":"Serum cytokines Th1, Th2, and Th17 expression profiling in active lupus Nephritis-IV: from a Southern Chinese Han population","volume":"2016","author":"Sigdel","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.biopha.2021.111289_bib0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2169\/internalmedicine.56.7668","article-title":"Treatment of vasodilator-resistant mixed connective tissue disease-associated pulmonary arterial hypertension with glucocorticoid and cyclophosphamide","volume":"56","author":"Sugawara","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.biopha.2021.111289_bib0170","first-page":"141","article-title":"Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with rapamycin","volume":"13","author":"Salehi","year":"2016","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.biopha.2021.111289_bib0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/icb.2017.53","article-title":"Cytokines in systemic lupus erythematosus: far beyond Th1\/Th2 dualism lupus: cytokine profiles","volume":"95","author":"Guimaraes","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.biopha.2021.111289_bib0180","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/0961203319877239","article-title":"Restoring T-helper 17 cell\/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus","volume":"28","author":"Chu","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.biopha.2021.111289_bib0185","first-page":"659","article-title":"Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1\/Th2\/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells","volume":"8","author":"Yuan","year":"2015","journal-title":"Int. J. Ophthalmol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:29:41Z","timestamp":1760099381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":37,"alternative-id":["S0753332221000743"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111289","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111289"}}